Answer
Breastfeeding should be discontinued during treatment with Koselugo (selumetinib), because a risk to the breastfed child cannot be excluded and it is unknown whether selumetinib or its metabolites enter human milk.
Sources for this answer
- Koselugo 5 mg granules in capsule for openingAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked